Latest developments in the biology and management of uveal melanoma

Current Oncology Reports

Volumn 15, Issue 6, 2013, Pages 509-516

  Patel, Sapna P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biology; Mutations; Prognosis; Therapy; Uveal melanoma

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CIXUTUMUMAB; DACARBAZINE; EVEROLIMUS; FOTEMUSTINE; GANETESPIB; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; PASIREOTIDE; RECOMBINANT ALPHA2B INTERFERON; SELUMETINIB; SOTRASTAURIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; VORINOSTAT; YTTRIUM 90;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CELL THERAPY; CHEMOEMBOLIZATION; GENE MUTATION; GNA11 GENE; GNAQ GENE; HUMAN; LIVER METASTASIS; MOLECULAR BIOLOGY; MONOSOMY; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SYSTEMIC THERAPY; T LYMPHOCYTE; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; HUMANS; LIVER NEOPLASMS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84890099122     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0348-y     Document Type: Note

References (79)

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-5. doi: 10.1016/j.ophtha.2011.01.040.
2. Schmidt-Pokrzywniak A, Jockel KH, Bornfeld N, Sauerwein W, Stang A. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology. 2009;116(2):340-8. doi: 10.1016/j.ophtha.2008.09.040.
3. Lutz JM, Cree I, Sabroe S, Kvist TK, Clausen LB, Afonso N, et al. Occupational risks for uveal melanoma results from a case-control study in nine European countries. Cancer Causes Control. 2005;16(4):437-47. doi: 10.1007/s10552-004-5029-6.
4. Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J. Sunlight exposure and pathogenesis of uveal melanoma. Surv Ophthalmol. 2004;49(4):419-28. doi: 10.1016/j.survophthal.2004.04.009.
5. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin N Am. 2005;18(1):143-50. doi: 10.1016/j.ohc.2004.07.003.
6. Sato T, Han F, Yamamoto A. The biology and management of uveal melanoma. Curr Oncol Rep. 2008;10(5):431-8.
7. Damato B. Treatment of primary intraocular melanoma. Expert Rev Anticancer Ther. 2006;6(4):493-506. doi: 10.1586/14737140.6.4.493.
8. Gragoudas ES, Marie LA. Uveal melanoma: proton beam irradiation. Ophthalmol Clin N Am. 2005;18(1):111-8. doi: 10.1016/j.ohc.2004.08.002.
9. Vavvas D, Kim I, Lane AM, Chaglassian A, Mukai S, Gragoudas E. Posterior uveal melanoma in young patients treated with proton beam therapy. Retina. 2010;30(8):1267-71. doi: 10.1097/IAE.0b013e3181cfdfad.
10. Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol Oncol Clin N Am. 2012;26(6):1169-84. doi: 10.1016/j.hoc.2012.08.004.
11. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Investig Ophthalmol Vis Sci. 2003;44(11):4651-9.
12. Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond). 2013;27(2):230-42. doi: 10.1038/eye.2012.255.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. doi: 10.1038/nature00766.
14. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol. 1994;131(1):72-7.
15. Cruz 3rd F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63(18):5761-6.
16. Rimoldi D, Salvi S, Lienard D, Lejeune FJ, Speiser D, Zografos L, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003;63(18):5712-5.
17. Cohen Y, Goldenberg-Cohen N, Parrella P, Chowers I, Merbs SL, Pe'er J, et al. Lack of BRAF mutation in primary uveal melanoma. Investig Ophthalmol Vis Sci. 2003;44(7):2876-8.
18. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599-602. doi: 10.1038/nature07586.
19. •• Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-9. doi: 10.1056/NEJMoa1000584. This article first reported mutations in GNA11 in uveal melanoma and modeled its role in activation of the MAPK pathway.
20. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol. 2001;194(2):201-6. doi: 10.1002/1096-9896(200106)194:2<201::AID-PATH840>3. 0.CO;2-O.
21. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997;104(5):777-80.
22. Eagle Jr RC. The pathology of ocular cancer. Eye (Lond). 2013;27(2):128-36. doi: 10.1038/eye.2012.237.
23. Finger PT. The 7th edition AJCC staging system for eye cancer: an international language for ophthalmic oncology. Arch Pathol Lab Med. 2009;133(8):1197-8. doi: 10.1043/1543-2165-133.8.1197.
24. Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243-52. doi: 10.1038/eye.2012.256.
25. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst. 1990;82(22):1765-9.
26. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222-5.
27. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011;118(2):396-401. doi: 10.1016/j.ophtha.2010.05.023.
28. Singh AD, Aronow ME, Sun Y, Bebek G, Saunthararajah Y, Schoenfield LR, et al. Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array. Investig Ophthalmol Vis Sci. 2012;53(7):3331-9. doi: 10.1167/iovs.11-9027.
29. Lake SL, Coupland SE, Taktak AF, Damato BE. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Investig Ophthalmol Vis Sci. 2010;51(10):4884-91. doi: 10.1167/iovs.09-5083.
30. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205-9. doi: 10.1158/0008-5472.CAN-04-1750.
31. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res. 2010;35(9):857-63. doi: 10.3109/02713683.2010.493265.
32. •• Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12(4):461-8. doi: 10.2353/jmoldx.2010.090220. This article provided validation of gene expression profiling data and their utility in prognostication.
33. Harbour JW, Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr. 2013;5. doi: 10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618.
34. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-3. doi: 10.1126/science.1194472.
35. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179. doi: 10.1186/1479-5876-10-179.
36. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856-9. doi: 10.1136/jmedgenet-2011-100156.
37. •• Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408-16. doi: 10.1158/1078-0432.CCR-11-0946. This study showed histone deacetylase inhibitors as a class are capable of inducing grown inhibition in uveal melanoma.
38. Metz CH, Scheulen M, Bornfeld N, Lohmann D, Zeschnigk M. Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med. 2013;2(2):208-15. doi: 10.1002/cam4.61.
39. Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer Res. 2012;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309.
40. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Thiel E, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 2011;80(1-2):57-62. doi: 10.1159/000328283.
41. Pinzani P, Mazzini C, Salvianti F, Massi D, Grifoni R, Paoletti C, et al. Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression. Melanoma Res. 2010;20(4):303-10. doi: 10.1097/CMR.0b013e32833906e3.
42. Schuster R, Bechrakis NE, Stroux A, Busse A, Schmittel A, Scheibenbogen C, et al. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res. 2007;13(4):1171-8. doi: 10.1158/1078-0432.CCR-06-2329.
43. Frenkel S, Zloto O, Pe'er J, Barak V. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Investig Ophthalmol Vis Sci. 2013;54(1):490-3. doi: 10.1167/iovs.12-10228.
44. Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe'er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res. 2011;31(1):345-9.
45. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe'er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27(4A):1897-900.
46. Augsburger JJ, Correa ZM, Trichopoulos N. Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival. Am J Ophthalmol. 2011;152(1):5-9 e1. doi: 10.1016/j.ajo.2011.03.004.
47. Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. Am Soc Clin Oncol Educ Book. 2013;2013:382-7. doi: 10.1200/EdBook-AM.2013.33.382.
48. Wen JC, Sai V, Straatsma BR, McCannel TA. Radiation-related cancer risk associated with surveillance imaging for metastasis from choroidal melanoma. JAMA Ophthalmol. 2013;131(1):56-61. doi: 10.1001/jamaophthalmol.2013.564.
49. Desjardins L, Dorval T, Lévy C, Cojean I, Schlienger P, Salmon RJ, et al. Randomized study on adjuvant therapy by DTIC in choroidal melanoma. Ophthalmologie. 1998;12:168-73.
50. Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009;116(11):2206-12. doi: 10.1016/j.ophtha.2009.04. 044.
51. Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res. 2008;18(3):220-4. doi: 10.1097/CMR.0b013e32830317de.
52. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74(5):574-7.
53. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol. 2009;35(11):1192-7. doi: 10.1016/j.ejso.2009.02.016.
54. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93(8):1042-6. doi: 10.1136/bjo.2008.153684.
55. Helton WS. Ocular melanoma metastatic to the liver: the role of surgery in multimodality therapy. Ann Surg Oncol. 2004;11(3):242-4.
56. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17(4):578-83. doi: 10.1093/annonc/mdl009.
57. Pingpank JF, Hughes MS, Faries MB, Zager JS, Alexander HR, Royal R, et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol. 2010;28(18 Suppl), LBA8512.
58. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15(4):297-304.
59. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260(7):974-6.
60. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33(5):474-80. doi: 10.1097/COC.0b013e3181b4b065.
61. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26(33):5436-42. doi: 10.1200/JCO.2008.16.0705.
62. Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol. 2013;36(1):158-65. doi: 10.1007/s00270-012-0373-5.
63. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665-70.
64. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003;13(3):303-6. doi: 10.1097/01.cmr.0000056231.78713.e2.
65. Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhonen S, Seppa H, Korpela M, et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res. 2005;15(4):291-6.
66. Kivela T, Suciu S, Hansson J, Kruit WH, Vuoristo MS, Kloke O, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39(8):1115-20.
67. Dorval T, Fridman WH, Mathiot C, Pouillart P. Interleukin-2 therapy for metastatic uveal melanoma. Eur J Cancer. 1992;28A(12):2087.
68. Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61(1):41-8. doi: 10.1007/s00262-011-1089-0.
69. Kelderman S, van der Kooij MK, van den Eertwegh AJ, Soetekouw PM, Jansen RL, van den Brom RR, et al. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013. doi: 10.3109/0284186X.2013.786839.
70. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013;23(1):79-81. doi: 10.1097/CMR.0b013e32835b554f.
71. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3.
72. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, et al. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011;21(4):357-63. doi: 10.1097/CMR.0b013e3283471073.
73. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009;15(1):324-9. doi: 10.1158/1078-0432.CCR-08- 2243.
74. Penel N, Delcambre C, Durando X, Clisant S, Hebbar M, Negrier S, et al. O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Investig New Drugs. 2008;26(6):561-5. doi: 10.1007/s10637-008-9143-2.
75. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012;22(6):440-6. doi: 10.1097/CMR.0b013e328358b373.
76. •• Carvajal RD, Sosman JA, Quevedo F, Milhem MM, Joshua AM, Kudchadkar RR, et al. Phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma. J Clin Oncol. 2013;31(18 Suppl), CRA9003. This is the first prospective, randomized phase II study to demonstrate an improvement in progression-free survival in uveal melanoma patients receiving a MEK inhibitor.
77. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther. 2013;12(5):768-76. doi: 10.1158/1535-7163.MCT-12-1020.
78. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One. 2012;7(7):e40439. doi: 10.1371/journal.pone.0040439.
79. •• Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. This study shows MEK activity can be enhanced with the addition of phosphatidylinositol 3-kinase inhibitors in vitro.